Ma Yinglong is one of the first Chinese time-honored enterprises recognized by the Ministry of Commerce. It was founded in 1582 AD. For a long time, Ma Yinglong has been committed to the professional development of the pharmaceutical industry, insisting on the core positioning of the anorectal hemorrhoid treatment field. After years of sustained, rapid and healthy development, it has now grown into a company involved in pharmaceutical manufacturing, pharmaceutical research and development, pharmaceutical wholesale and retail, chain hospitals, etc. A professional, multi-functional and international listed company in multiple fields.
The company has complete production functions and can produce more than 30 dosage forms. It can produce more than 300 kinds of drugs with approved national drug brands. It has more than 20 exclusive varieties, and 18 varieties with approved national drug brands have been selected into the " "National Essential Drugs List", 37 varieties are selected into the "National Medical Insurance List", among which Mayinglong Musk Hemorrhoid Ointment, Musk Hemorrhoid Suppository, Longzhu Ointment, and Mayinglong Babao Eye Ointment are the company's exclusive products. The production facilities are advanced, and the technical level of the production lines and supporting facilities for the main varieties is already at the leading level in the country.
The company focuses on its core positioning and carries out series of drug research and development. Currently, there are 7 varieties of anorectal hemorrhoid treatment products on sale, and 3 hemorrhoid treatment projects are under development, covering ointments, suppositories, Western medicine oral tablets, Chinese medicine oral tablets, lotions, capsules, creams and gels, and aerosols. It has a variety of dosage forms such as dosage forms, powders, and granules, and has 6 anorectal hemorrhoid treatment varieties under development and 8 other projects under development. The company has also developed a series of eye care cosmeceutical products and is actively entering the cosmeceutical market, with 11 projects currently under development.
The company currently has a technical team with well-staffed, reasonable structure and complementary advantages, as well as a group of subject leaders engaged in research on drug synthesis, traditional Chinese medicine extraction, pharmaceutical engineering, pharmacology and toxicology, and clinical trial evaluation. people. The company has established long-term strategic cooperative relationships with many scientific research institutions such as Peking University School of Pharmacy and China Pharmaceutical University. With the approval of the Ministry of Personnel, the company and Peking University *** jointly established a postdoctoral workstation. In 2009, the technology center of Mayinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by the National Development and Reform Commission, the Ministry of Science and Technology and other five ministries. The Mayinglong innovative drug research and development team was recognized by the Organization Department of the Hubei Provincial Party Committee as one of the first batch of "Hubei Provincial Key Industrial Innovation team".
According to statistics from the Southern Institute of Medical Economics of the State Food and Drug Administration, Ma Yinglong’s share of the hemorrhoid drug retail market exceeds 40%, making it the number one brand in the field of hemorrhoid treatment.
The company has established a relatively complete marketing management system and a nationwide marketing network platform, and has established long-term cooperative relationships with more than 300 companies that are at the forefront of the domestic pharmaceutical distribution field. Its products are exported to Southeast Asia, Europe and the United States. mainland.
Ma Yinglong and its subsidiaries have passed the GMP and GSP quality management specification system certifications of the State Food and Drug Administration respectively, and obtained the environmental management system ISO14000 and occupational safety and health management system OHSAS18000 certification issued by the international authoritative organization SGS. It was the first to achieve the "three certifications" in the pharmaceutical industry. In the 2010 "Top 500 Most Valuable Brands in China" jointly evaluated by World Brand Laboratory and World Managers Weekly, Ma Yinglong ranked 210th, with a brand value of 4.321 billion yuan. In 2005, Ma Yinglong won the title of "China's Most Influential Hemorrhoid Drug Brand" in the joint selection of six public media including People's Daily, China Enterprise Culture Promotion Association, and China Quality and Brand Magazine. In 2006, Ma Yinglong was awarded the "China Well-known Trademark" recognized by the State Administration for Industry and Commerce, becoming the only "China Well-known Trademark" in the field of hemorrhoid treatment in China. In 2009, Ma Yinglong was selected as one of the "Top 15 OTC Brand Enterprises in China" by the China Over-the-Counter Drug Association.
The company's shares were listed on the Shanghai Stock Exchange in 2004, thus gaining access to continuous financing and a platform for standardized operations. The company's stocks have been selected as sample stocks of the China Listed Corporate Governance Index and the Shanghai Stock Exchange Social Responsibility Index by the Shanghai Stock Exchange and China Securities Index Corporation. The company has been awarded the "Excellent Board of Directors Award" and "Listed Company with the Most Important Shareholders' Equity", indicating that the company's corporate governance level has been highly recognized by the public, securities institutions and experts.